CLOCK and neoplasm: Sulli et al. (2018) proposed that the pharmacological modulation of the circadian clock by REV-ERBs agonists impairs tumor proliferation, inhibiting de novo lipogenesis and autophagy, which are well-known hallmarks of tumor cells [242].